SUMMARY
Panixine DisperDose ® (cephalexin tablets for oral suspension)
Cephalexin, USP is a semisynthetic cephalosporin antibiotic intended for oral administration. It is 7-(D-α-amino-α-phenylacetamido)-3-methyl-3-cephem-4-carboxylic acid monohydrate.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Panixine DisperDose and other antibacterial drugs, Panixine DisperDose should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Cephalexin is indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms:
Respiratory tract infections caused by S. pneumoniae and S. pyogenes (Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.)
Otitis media due to S. pneumoniae, H. influenzae, staphylococci, streptococci and M. catarrhalis
Skin and skin structure infections caused by staphylococci and/or streptococci
Bone infections caused by staphylococci and/or P. mirabilis
Genitourinary tract infections, including acute prostatitis, caused by E. coli, P. mirabilis, and K. pneumoniae
Note — Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated.
|
|
NEWS HIGHLIGHTS
Published Studies Related to Panixine Disperdose (Cephalexin)
Randomized controlled trial of cephalexin versus clindamycin for uncomplicated pediatric skin infections. [2011.03] OBJECTIVE: To compare clindamycin and cephalexin for treatment of uncomplicated skin and soft tissue infections (SSTIs) caused predominantly by community-associated (CA) methicillin-resistant Staphylococcus aureus (MRSA). We hypothesized that clindamycin would be superior to cephalexin (an antibiotic without MRSA activity) for treatment of these infections... CONCLUSIONS: There is no significant difference between cephalexin and clindamycin for treatment of uncomplicated pediatric SSTIs caused predominantly by CA-MRSA. Close follow-up and fastidious wound care of appropriately drained, uncomplicated SSTIs are likely more important than initial antibiotic choice.
Effects of sodium bicarbonate and ammonium chloride pre-treatments on PEPT2 (SLC15A2) mediated renal clearance of cephalexin in healthy subjects. [2011] PEPT2 mediates the H(+) gradient-driving reabsorption of di- and tri-peptides, and various peptidomimetic compounds in the kidney... This effect was more obvious for the PEPT2*2/*2.
Efficacy and tolerability of once-daily cephalexin in canine superficial pyoderma: an open controlled study. [2008.08] OBJECTIVES: The aims of this study were to evaluate the efficacy and tolerability of oral cephalexin given at 30 mg/kg once daily in dogs with superficial pyoderma and to compare them with those of oral cephalexin given at 15 mg/kg twice daily. METHODS: Twenty dogs with superficial pyoderma were treated with cephalexin at 30 to 60 mg/kg orally once daily (group A) and compared with 20 dogs treated at a dose of 15 to 30 mg/kg orally twice daily (group B)...
randomized, double-blind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community-acquired methicillin-resistant Staphylococcus aureus infection. [2007.11] Empirical use of beta-lactam antibiotics, the preferred agents for treating uncomplicated skin and soft tissue infections, may no longer be appropriate for these infections because of the increasing prevalence of community strains of methicillin-resistant Staphylococcus aureus (MRSA)...
Randomized, Double-Blind, Placebo-Controlled Trial of Cephalexin for Treatment of Uncomplicated Skin Abscesses in a Population at Risk for Community Methicillin-Resistant Staphylococcus aureus Infection. [2007.09.10] Background- Empirical use of beta-lactam antibiotics, the preferred agents for treating uncomplicated skin and soft-tissue infections, may no longer be appropriate for these infections because of increasing prevalence of community strains of methicillin-resistant Staphylococcus aureus (MRSA)...
Clinical Trials Related to Panixine Disperdose (Cephalexin)
A Study to Compare Cefdinir and Cephalexin for the Treatment of Mild to Moderate Uncomplicated Skin Infections [Completed]
The purpose of this study is to compare the efficacy and tolerability of cefdinir to that of
cephalexin in patients with mild to moderate uncomplicated skin/skin structure infections.
Comparison of Cephalexin Versus Clindamycin for Empiric Treatment of Suspected CA-MRSA Skin Infections [Recruiting]
The purpose of this study is to help define the role of antibiotics in the treatment of
pediatric skin infections caused by CA-MRSA. We hypothesize that treatment with cephalexin,
a penicillin-like antibiotic to which CA-MRSA would be expected to be resistant, does not
result in poorer outcomes than treatment with clindamycin, an antibiotic to which CA-MRSA is
most often susceptible.
Ciprofloxacin Compared With Cephalexin in Treating Patients With Bladder Cancer [Active, not recruiting]
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the
development or recurrence of cancer. It is not yet known whether ciprofloxacin is more
effective than cephalexin in preventing cancer recurrence in patients who are undergoing
surgery to treat bladder cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of ciprofloxacin with that
of cephalexin in preventing recurrence of cancer in patients who are undergoing surgery for
bladder cancer.
The Impact of Treating Staphylococcus Aureus Infection and Colonization on the Clinical Severity of Atopic Dermatitis [Recruiting]
Staphylococcus aureus (S. aureus) infection is perceived not only as a common secondary
complication of atopic dermatitis (AD), but also as a culprit in the worsening of this
condition. In addition, the recent development of community acquired methicillin-resistant
S. aureus (CA-MRSA) has presented a new challenge to our management of AD, both in treatment
of acute infections and maintenance therapy. We would like to perform a randomized
investigator-blinded placebo-controlled study of children aged 6 months to 17 years with
moderate to severe atopic dermatitis with clinical signs of secondary bacterial infection to
study: 1) the prevalence of CA-MRSA in our patient population; 2) the relationship of
sensitivity of the S. aureus organism cultured from the infected lesion(s) to clinical
response to oral cephalexin therapy and severity of the AD; and 3) whether concurrent
treatment of S. aureus infection initially with nasal mupirocin ointment and sodium
hypochlorite (bleach) baths can result in long-term S. aureus eradication and clinical
stability.
Placebo Controlled Study of Antibiotic Treatment of Soft Tissue Infection [Completed]
This study is to determine whether antibiotic therapy is needed for patients with non-life
threatening soft tissue infections. Most patients with these soft tissue infections are
presently treated with antibiotics. Many of these infections resolve without proper
antibiotic treatment. Treatment of patients with antibiotics after surgical drainage of an
abscess may not be necessary and indiscriminate use of antibiotics may lead to colonization
by drug-resistant organisms. Subsequent infection by drug resistant organisms may limit the
choice of antibiotics in more complicated infections. A comparison between antibiotic
treatment and no antibiotic treatment in surgically treated, uncomplicated soft tissue
infections is needed to address this very important question.
|
PATIENT REVIEWS / RATINGS / COMMENTSBased on a total of 7 ratings/reviews, Panixine Disperdose has an overall score of 8. The effectiveness score is 8 and the side effect score is 7.14. The scores are on ten point scale: 10 - best, 1 - worst. Below are selected reviews: the highest, the median and the lowest rated.
| | Panixine Disperdose review by 20 year old female patient | | | Rating |
| Overall rating: | |           |
| Effectiveness: | | Highly Effective |
| Side effects: | | Mild Side Effects | | | Treatment Info |
| Condition / reason: | | Skin Infection |
| Dosage & duration: | | 500 mg taken 3 times per day for the period of 10 days |
| Other conditions: | | None |
| Other drugs taken: | | None | | | Reported Results |
| Benefits: | | Treatment of skin infection. |
| Side effects: | | Vaginal yeast infection. |
| Comments: | | Take 1 capsule by mouth three times daily for 10 days. |
|
| | Panixine Disperdose review by care giver of 1 year old female patient | | | Rating |
| Overall rating: | |           |
| Effectiveness: | | Highly Effective |
| Side effects: | | Severe Side Effects | | | Treatment Info |
| Condition / reason: | | streptoccocus:severe sore throat,high fever(104.4) |
| Dosage & duration: | | 4ml by mouth (dosage frequency: 3 times a day) for the period of 7 days |
| Other conditions: | | none |
| Other drugs taken: | | one doze of penicilin;occasionally tylenol for fever | | | Reported Results |
| Benefits: | | the baby was totally cured in 7 days |
| Side effects: | | because of the antibiotic several days after appeared a severe yeast infection |
| Comments: | | the baby was sick for 4 days already but her doctor didnt see anything serious.Her fever was already 104.4 and it was difficult to drop it. she couldnt eat nore sleep and was crying days and nights because her throat was very very sore.Finally we took her into emergency room and they found out that she has strep. they gave us cephalexin. the baby felt relief on her 4th day.she started to eat and play. no more fever. in 7 days, by the end of her treatment, she felt wonderful. the only problem was that several days after treatment she started to have an awful yeast infection.I beleive it was the side effect from antibiotic. it took us one more week to treat tha infection.
I rated the cephalexin as 8 'cause it took 4 days to feel relief(i think its a lot) and the side effect was quite sufficient too.overall I liked this medicine. |
|
| | Panixine Disperdose review by 38 year old female patient | | | Rating |
| Overall rating: | |           |
| Effectiveness: | | Ineffective |
| Side effects: | | Severe Side Effects | | | Treatment Info |
| Condition / reason: | | mild local skin infection |
| Dosage & duration: | | 500 mg taken 1 x daily for the period of 2 days |
| Other conditions: | | none |
| Other drugs taken: | | none | | | Reported Results |
| Benefits: | | I cannot say whether this medication was or was not effective because I stopped taking it after 2 doses. I discontinued the medication because the side effects were severe and much worse than the condition prescribed for. |
| Side effects: | | About 24 hours after my second dose I developed sudden acute abdominal pain. I have never had a negative reaction to any medication before, and had rarely had any stomach pain in my life. This pain was so strong and intense almost like the pain of a labor contraction. But alas it was upper abdominal and not coming from my uteris. It came in waves and anything I ate or drank made it worse. I was very close to going to the ER. But since my temp, BP and HR were normal and I did not have any other obvious symptoms I toughed it out with a heating pad and curse words. After 2 days of this torture I finally feel the worst is over. But I will not take this med again. |
| Comments: | | The initial skin infection is clearing up. |
|
|
|
Page last updated: 2011-12-09
|